Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.

Arnaud BourdinAlberto A PapiJonathan CorrenJohann Christian VirchowMegan S RiceYamo DenizMichel DjandjiPaul RoweIan D Pavord

Published in: Allergy (2020)

Dupilumab significantly reduced severe exacerbations and improved lung function and asthma control in patients with type 2-high asthma on high-dose ICS at baseline.

Keyphrases

lung function
cystic fibrosis
chronic obstructive pulmonary disease
high dose
air pollution
atopic dermatitis
low dose
stem cell transplantation
early onset
allergic rhinitis
drug induced